Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Antibacterial Drug Resistance Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Antibacterial Drug Resistance Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Telavancin (Vibativ)
      • 1.3.3 Ceftaroline Fosamil (Teflaro/ Zinforo)
      • 1.3.4 Fidaxomicin (Dificid / Dificlir)
      • 1.3.5 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
      • 1.3.6 Dalbavancin (Dalvance/ Xydalba)
      • 1.3.7 Tedizolid Phosphate (Sivextro)
      • 1.3.8 Oritavancin (Orbactiv/ Nuvocid)
      • 1.3.9 Ceftolozane-Tazobactam (Zerbaxa)
      • 1.3.10 Ceftazidime-Avibactam (Avycaz/ Zavicefta)
      • 1.3.11 PHASE III DRUGS
    • 1.4 Market Segment by Application
      • 1.4.1 Global Antibacterial Drug Resistance Market Share by Application (2019-2025)
      • 1.4.2 Gram-Positive
      • 1.4.3 Gram-Negative
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Antibacterial Drug Resistance Market Size
      • 2.1.1 Global Antibacterial Drug Resistance Revenue 2014-2025
      • 2.1.2 Global Antibacterial Drug Resistance Sales 2014-2025
    • 2.2 Antibacterial Drug Resistance Growth Rate by Regions
      • 2.2.1 Global Antibacterial Drug Resistance Sales by Regions 2014-2019
      • 2.2.2 Global Antibacterial Drug Resistance Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Antibacterial Drug Resistance Sales by Manufacturers
      • 3.1.1 Antibacterial Drug Resistance Sales by Manufacturers 2014-2019
      • 3.1.2 Antibacterial Drug Resistance Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Antibacterial Drug Resistance Revenue by Manufacturers (2014-2019)
      • 3.2.2 Antibacterial Drug Resistance Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Antibacterial Drug Resistance Market Concentration Ratio (CR5 and HHI)
    • 3.3 Antibacterial Drug Resistance Price by Manufacturers
    • 3.4 Key Manufacturers Antibacterial Drug Resistance Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Antibacterial Drug Resistance Market
    • 3.6 Key Manufacturers Antibacterial Drug Resistance Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Telavancin (Vibativ) Sales and Revenue (2014-2019)
      • 4.1.2 Ceftaroline Fosamil (Teflaro/ Zinforo) Sales and Revenue (2014-2019)
      • 4.1.3 Fidaxomicin (Dificid / Dificlir) Sales and Revenue (2014-2019)
      • 4.1.4 Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio) Sales and Revenue (2014-2019)
      • 4.1.5 Dalbavancin (Dalvance/ Xydalba) Sales and Revenue (2014-2019)
      • 4.1.6 Tedizolid Phosphate (Sivextro) Sales and Revenue (2014-2019)
      • 4.1.7 Oritavancin (Orbactiv/ Nuvocid) Sales and Revenue (2014-2019)
      • 4.1.8 Ceftolozane-Tazobactam (Zerbaxa) Sales and Revenue (2014-2019)
      • 4.1.9 Ceftazidime-Avibactam (Avycaz/ Zavicefta) Sales and Revenue (2014-2019)
      • 4.1.10 PHASE III DRUGS Sales and Revenue (2014-2019)
    • 4.2 Global Antibacterial Drug Resistance Sales Market Share by Type
    • 4.3 Global Antibacterial Drug Resistance Revenue Market Share by Type
    • 4.4 Antibacterial Drug Resistance Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Antibacterial Drug Resistance Sales by Application

    6 United States

    • 6.1 United States Antibacterial Drug Resistance Breakdown Data by Company
    • 6.2 United States Antibacterial Drug Resistance Breakdown Data by Type
    • 6.3 United States Antibacterial Drug Resistance Breakdown Data by Application

    7 European Union

    • 7.1 European Union Antibacterial Drug Resistance Breakdown Data by Company
    • 7.2 European Union Antibacterial Drug Resistance Breakdown Data by Type
    • 7.3 European Union Antibacterial Drug Resistance Breakdown Data by Application

    8 China

    • 8.1 China Antibacterial Drug Resistance Breakdown Data by Company
    • 8.2 China Antibacterial Drug Resistance Breakdown Data by Type
    • 8.3 China Antibacterial Drug Resistance Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Antibacterial Drug Resistance Breakdown Data by Company
    • 9.2 Rest of World Antibacterial Drug Resistance Breakdown Data by Type
    • 9.3 Rest of World Antibacterial Drug Resistance Breakdown Data by Application
    • 9.4 Rest of World Antibacterial Drug Resistance Breakdown Data by Countries
      • 9.4.1 Rest of World Antibacterial Drug Resistance Sales by Countries
      • 9.4.2 Rest of World Antibacterial Drug Resistance Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 AAIPharma Services
      • 10.1.1 AAIPharma Services Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.1.4 Antibacterial Drug Resistance Product Introduction
      • 10.1.5 AAIPharma Services Recent Development
    • 10.2 ANTABIO
      • 10.2.1 ANTABIO Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.2.4 Antibacterial Drug Resistance Product Introduction
      • 10.2.5 ANTABIO Recent Development
    • 10.3 Abgentis
      • 10.3.1 Abgentis Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.3.4 Antibacterial Drug Resistance Product Introduction
      • 10.3.5 Abgentis Recent Development
    • 10.4 Abbott Laboratories
      • 10.4.1 Abbott Laboratories Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.4.4 Antibacterial Drug Resistance Product Introduction
      • 10.4.5 Abbott Laboratories Recent Development
    • 10.5 Absynth Biologics
      • 10.5.1 Absynth Biologics Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.5.4 Antibacterial Drug Resistance Product Introduction
      • 10.5.5 Absynth Biologics Recent Development
    • 10.6 Achaogen
      • 10.6.1 Achaogen Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.6.4 Antibacterial Drug Resistance Product Introduction
      • 10.6.5 Achaogen Recent Development
    • 10.7 Acino Holdings
      • 10.7.1 Acino Holdings Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.7.4 Antibacterial Drug Resistance Product Introduction
      • 10.7.5 Acino Holdings Recent Development
    • 10.8 Aventis Pharma
      • 10.8.1 Aventis Pharma Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.8.4 Antibacterial Drug Resistance Product Introduction
      • 10.8.5 Aventis Pharma Recent Development
    • 10.9 Austell Laboratories
      • 10.9.1 Austell Laboratories Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.9.4 Antibacterial Drug Resistance Product Introduction
      • 10.9.5 Austell Laboratories Recent Development
    • 10.10 Assembly Biosciences
      • 10.10.1 Assembly Biosciences Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Antibacterial Drug Resistance
      • 10.10.4 Antibacterial Drug Resistance Product Introduction
      • 10.10.5 Assembly Biosciences Recent Development
    • 10.11 Arpida
    • 10.12 Demuris
    • 10.13 Evolva Holding
    • 10.14 ContraFect
    • 10.15 Cerexa
    • 10.16 GSK
    • 10.17 InterMune
    • 10.18 Isis Pharmaceuticals
    • 10.19 Lyndra
    • 10.20 Microbecide
    • 10.21 Morphochem
    • 10.22 Nabriva Therapeutics
    • 10.23 NanoSafe Coatings
    • 10.24 Novexel
    • 10.25 Osel
    • 10.26 PENDOPHARM
    • 10.27 Pfizer
    • 10.28 VenatoRx Pharmaceuticals

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Antibacterial Drug Resistance Sales Channels
      • 11.2.2 Antibacterial Drug Resistance Distributors
    • 11.3 Antibacterial Drug Resistance Customers

    12 Market Forecast

    • 12.1 Global Antibacterial Drug Resistance Sales and Revenue Forecast 2019-2025
    • 12.2 Global Antibacterial Drug Resistance Sales Forecast by Type
    • 12.3 Global Antibacterial Drug Resistance Sales Forecast by Application
    • 12.4 Antibacterial Drug Resistance Forecast by Regions
      • 12.4.1 Global Antibacterial Drug Resistance Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Antibacterial Drug Resistance Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      In 2019, the market size of Antibacterial Drug Resistance is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Antibacterial Drug Resistance.

      This report studies the global market size of Antibacterial Drug Resistance, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Antibacterial Drug Resistance sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      AAIPharma Services
      ANTABIO
      Abgentis
      Abbott Laboratories
      Absynth Biologics
      Achaogen
      Acino Holdings
      Aventis Pharma
      Austell Laboratories
      Assembly Biosciences
      Arpida
      Demuris
      Evolva Holding
      ContraFect
      Cerexa
      GSK
      InterMune
      Isis Pharmaceuticals
      Lyndra
      Microbecide
      Morphochem
      Nabriva Therapeutics
      NanoSafe Coatings
      Novexel
      Osel
      PENDOPHARM
      Pfizer
      VenatoRx Pharmaceuticals

      Market Segment by Product Type
      Telavancin (Vibativ)
      Ceftaroline Fosamil (Teflaro/ Zinforo)
      Fidaxomicin (Dificid / Dificlir)
      Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
      Dalbavancin (Dalvance/ Xydalba)
      Tedizolid Phosphate (Sivextro)
      Oritavancin (Orbactiv/ Nuvocid)
      Ceftolozane-Tazobactam (Zerbaxa)
      Ceftazidime-Avibactam (Avycaz/ Zavicefta)
      PHASE III DRUGS

      Market Segment by Application
      Gram-Positive
      Gram-Negative

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Antibacterial Drug Resistance status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Antibacterial Drug Resistance manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Antibacterial Drug Resistance are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now